Composition of Bone Marrow and Spleen in Control and mHEL+ Reconstituted Mice
. | . | Bone marrow . | . | . | Spleen . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Donor . | Recipienta . | Cellularityb . | IgDa+c . | HEL bindingc . | Cellularityb . | IgDa+c . | HEL bindingc . | ||||
| . | (n) . | 106 . | 106 . | 106 . | 106 . | 106 . | 106 . | ||||
| Tg+ bim+/+ | Control (4) | 14.9 ± 2.5 | 1.2 ± 0.3 | 1.1 ± 0.4 | 17.8 ± 5.6 | 10.8 ± 3.5 | 10.4 ± 3.5 | ||||
| mHEL+ (8) | 10.3 ± 2.3 | 0.5 ± 0.2d | 0.4 ± 0.1e | 8.1 ± 6.1 | 0.3 ± 0.2f | 0.01 ± 0.03 | |||||
| Tg+ bim−/− | Control (4) | 15.5 ± 3.0 | 4.0 ± 0.6 | 3.6 ± 0.5 | 83.5 ± 68.3 | 66.1 ± 58.7 | 63.6 ± 57.3 | ||||
| mHEL+ (8) | 11.4 ± 3.2 | 1.1 ± 0.5d | 0.9 ± 0.3e | 20.6 ± 11.9 | 1.7 ± 0.9f | 0.07 ± 0.1 | |||||
. | . | Bone marrow . | . | . | Spleen . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Donor . | Recipienta . | Cellularityb . | IgDa+c . | HEL bindingc . | Cellularityb . | IgDa+c . | HEL bindingc . | ||||
| . | (n) . | 106 . | 106 . | 106 . | 106 . | 106 . | 106 . | ||||
| Tg+ bim+/+ | Control (4) | 14.9 ± 2.5 | 1.2 ± 0.3 | 1.1 ± 0.4 | 17.8 ± 5.6 | 10.8 ± 3.5 | 10.4 ± 3.5 | ||||
| mHEL+ (8) | 10.3 ± 2.3 | 0.5 ± 0.2d | 0.4 ± 0.1e | 8.1 ± 6.1 | 0.3 ± 0.2f | 0.01 ± 0.03 | |||||
| Tg+ bim−/− | Control (4) | 15.5 ± 3.0 | 4.0 ± 0.6 | 3.6 ± 0.5 | 83.5 ± 68.3 | 66.1 ± 58.7 | 63.6 ± 57.3 | ||||
| mHEL+ (8) | 11.4 ± 3.2 | 1.1 ± 0.5d | 0.9 ± 0.3e | 20.6 ± 11.9 | 1.7 ± 0.9f | 0.07 ± 0.1 | |||||
Recipient mice were C57BL/6 (control) or C57BL/6 mHEL transgene positive.
Cellularity was determined by viable counts after red cell removal and are given per femur and per spleen.
IgDa and HEL-binding cell counts are based on the proportion of cells staining positive by flow cytometry immediately ex vivo and whole organ cell counts.
P = 0.01.
P < 0.001.
P = 0.001.